Full Description
Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.
Contents
Chapter 1: Health as a GoodChapter 2: Decision-Making in Public HealthChapter 3: Definition and ConceptsChapter 4: HTA Decision Analysis frameworkChapter 5: Early HTA AdviceChapter 6: Overview of Market Access AgreementsChapter 7: External Reference PricingChapter 8: Gap between Payers and RegulatorsChapter 9: Early Access ProgramsChapter 10: Market Access of Orphan DrugsChapter 11: Market Access of Vaccines in Developed CountriesChapter 12: FranceChapter 13: GermanyChapter 14: ItalyChapter 15: SpainChapter 16: SwedenChapter 17: United KingdomChapter 18: The United StatesChapter 19: JapanChapter 20: China
